Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 30.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Cert |
| 19.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai |
| 11.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai |
| 17.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 17.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Unternehmen & Branche
| Name | Clene Inc. |
|---|---|
| Ticker | CLNN |
| CIK | 0001822791 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 56,4 Mio. USD |
| Beta | 0,62 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 200,000 | -26,173,000 | 18,131,000 | -17,592,000 | |
| 2025-09-30 | 10-Q | 15,000 | -8,777,000 | 22,311,000 | -12,357,000 | |
| 2025-06-30 | 10-Q | 27,000 | -7,419,000 | 22,125,000 | -8,550,000 | |
| 2025-03-31 | 10-Q | 81,000 | -751,000 | 25,314,000 | -4,973,000 | |
| 2024-12-31 | 10-K | 342,000 | -39,400,000 | 27,337,000 | -8,857,000 | |
| 2024-09-30 | 10-Q | 87,000 | -7,986,000 | 31,569,000 | -4,125,000 | |
| 2024-06-30 | 10-Q | 91,000 | -6,785,000 | 40,330,000 | -504,000 | |
| 2024-03-31 | 10-Q | 73,000 | -11,080,000 | 45,069,000 | 4,264,000 | |
| 2023-12-31 | 10-K | 654,000 | -49,504,000 | 52,341,000 | 13,390,000 | |
| 2023-09-30 | 10-Q | 108,000 | -2,418,000 | 60,433,000 | 21,400,000 | |
| 2023-06-30 | 10-Q | 269,000 | -25,143,000 | 67,845,000 | 21,527,000 | |
| 2023-03-31 | 10-Q | 107,000 | -11,770,000 | 39,888,000 | -1,628,000 | |
| 2022-12-31 | 10-K | 473,000 | -29,918,000 | 44,493,000 | 3,237,000 | |
| 2022-09-30 | 10-Q | 174,000 | -10,976,000 | -0.17 | 36,004,000 | -9,319,000 |
| 2022-06-30 | 10-Q | 35,000 | -4,534,000 | -0.07 | 44,542,000 | -563,000 |
| 2022-03-31 | 10-Q | 30,000 | -13,354,000 | 53,361,000 | 2,017,000 | |
| 2021-12-31 | 10-K | 723,000 | -9,740,000 | 63,063,000 | 12,597,000 | |
| 2021-09-30 | 10-Q | 110,000 | 28,944,000 | 0.42 | 73,037,000 | 5,686,000 |
| 2021-06-30 | 10-Q | 201,000 | -3,351,000 | -0.05 | 73,284,000 | -25,925,000 |
| 2021-03-31 | 10-Q | 213,000 | -39,756,000 | 58,531,000 | -36,076,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -61,345 | 6.14 | -376,658.30 | -513,1% | |
| 2026-04-20 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -4,318 | 6.12 | -26,426.16 | -36,0% | |
| 2026-04-17 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -25,040 | 6.43 | -161,007.20 | -219,3% | |
| 2026-04-16 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -7,748 | 6.40 | -49,587.20 | -67,5% | |
| 2026-04-15 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -6,374 | 6.48 | -41,303.52 | -56,3% | |
| 2026-04-02 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -24,925 | 4.81 | -119,889.25 | -163,3% | |
| 2026-04-01 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -4,278 | 4.97 | -21,261.66 | -29,0% | |
| 2026-02-03 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -5,559 | 4.10 | -22,791.90 | -31,0% | |
| 2026-02-02 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -3,800 | 4.04 | -15,352.00 | -20,9% | |
| 2026-01-30 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -5,686 | 4.13 | -23,483.18 | -32,0% | |
| 2026-01-29 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -15,284 | 4.32 | -66,026.88 | -89,9% | |
| 2026-01-28 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -8,717 | 4.91 | -42,800.47 | -58,3% | |
| 2026-01-27 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -4,139 | 5.08 | -21,026.12 | -28,6% | |
| 2026-01-26 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -6,418 | 5.02 | -32,218.36 | -43,9% | |
| 2026-01-23 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -5,556 | 5.27 | -29,280.12 | -39,9% | |
| 2026-01-22 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -12,665 | 5.32 | -67,377.80 | -91,8% | |
| 2026-01-21 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -12,119 | 5.05 | -61,200.95 | -83,4% | |
| 2026-01-20 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -12,432 | 4.80 | -59,673.60 | -81,3% | |
| 2026-01-16 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -7,923 | 5.13 | -40,644.99 | -55,4% | |
| 2026-01-15 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -12,563 | 5.10 | -64,071.30 | -87,3% | |
| 2026-01-14 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -19,621 | 5.12 | -100,459.52 | -136,8% | |
| 2026-01-13 | MATLIN DAVID J | Director | Open Market Purchase | 33,333 | 6.50 | 216,664.50 | +295,1% | |
| 2026-01-13 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -26,105 | 4.89 | -127,653.45 | -173,9% | |
| 2026-01-12 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -32,705 | 5.50 | -179,877.50 | -245,0% | |
| 2026-01-09 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -9,075 | 6.27 | -56,900.25 | -77,5% | |
| 2026-01-08 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -3,195 | 6.09 | -19,457.55 | -26,5% | |
| 2026-01-07 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -3,938 | 6.29 | -24,770.02 | -33,7% | |
| 2026-01-06 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -3,111 | 6.04 | -18,790.44 | -25,6% | |
| 2026-01-05 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -5,869 | 5.87 | -34,451.03 | -46,9% | |
| 2026-01-02 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -4,015 | 5.73 | -23,005.95 | -31,3% | |
| 2025-12-31 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -13,095 | 5.81 | -76,081.95 | -103,6% | |
| 2025-12-30 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -4,138 | 6.03 | -24,952.14 | -34,0% | |
| 2025-12-29 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -8,096 | 5.95 | -48,171.20 | -65,6% | |
| 2025-12-26 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -3,350 | 6.32 | -21,172.00 | -28,8% | |
| 2025-12-24 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -1,490 | 6.27 | -9,342.30 | -12,7% | |
| 2025-12-23 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -6,831 | 6.27 | -42,830.37 | -58,3% | |
| 2025-12-22 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -4,367 | 6.54 | -28,560.18 | -38,9% | |
| 2025-12-19 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -5,582 | 6.45 | -36,003.90 | -49,0% | |
| 2025-12-18 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -5,816 | 6.33 | -36,815.28 | -50,1% | |
| 2025-12-17 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -2,884 | 6.61 | -19,063.24 | -26,0% | |
| 2025-12-16 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -7,030 | 6.31 | -44,359.30 | -60,4% | |
| 2025-12-15 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -10,580 | 6.49 | -68,664.20 | -93,5% | |
| 2025-12-12 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -7,603 | 6.79 | -51,624.37 | -70,3% | |
| 2025-12-11 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -10,907 | 6.81 | -74,276.67 | -101,2% | |
| 2025-12-10 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -9,921 | 6.42 | -63,692.82 | -86,8% | |
| 2025-12-09 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -15,031 | 5.95 | -89,434.45 | -121,8% | |
| 2025-12-08 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -21,463 | 5.70 | -122,339.10 | -166,7% | |
| 2025-12-05 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -37,235 | 5.94 | -221,175.90 | -301,3% | |
| 2025-12-04 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -72,748 | 6.73 | -489,594.04 | -666,9% | |
| 2025-12-03 | Ugwumba Chidozie | 10% Owner | Open Market Sale | -56,577 | 7.86 | -444,695.22 | -605,8% | |
| 2025-08-21 | General Resonance LLC | 10% Owner | Open Market Sale | -3,401 | 5.34 | -18,161.34 | -24,7% | |
| 2025-06-04 | General Resonance LLC | 10% Owner | Open Market Sale | -600 | 4.04 | -2,424.00 | -3,3% | |
| 2025-06-02 | General Resonance LLC | 10% Owner | Open Market Sale | -600 | 4.12 | -2,472.60 | -3,4% | |
| 2025-05-30 | General Resonance LLC | 10% Owner | Open Market Sale | -410 | 2.80 | -1,148.00 | -1,6% | |
| 2025-05-29 | General Resonance LLC | 10% Owner | Open Market Sale | -410 | 2.73 | -1,119.30 | -1,5% | |
| 2025-05-28 | General Resonance LLC | 10% Owner | Open Market Sale | -420 | 2.60 | -1,089.90 | -1,5% | |
| 2025-05-27 | General Resonance LLC | 10% Owner | Open Market Sale | -420 | 2.45 | -1,029.00 | -1,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.